Area of research
Neurology · Cellular and Molecular Neuroscience
Research interest
Research interests include Parkinson's Disease Mechanisms and Treatments, Neurological disorders and treatments, Neurological diseases and metabolism, and Nuclear Receptors and Signaling.
TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations
Iron-sulfur cluster loss in mitochondrial CISD1 mediates PINK1 loss-of-function phenotypes
Embracing Monogenic Parkinson's Disease: The <scp>MJFF</scp> Global Genetic <scp>PD</scp> Cohort
Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
GBA-associated PD: chances and obstacles for targeted treatment strategies
GDAP1 loss of function inhibits the mitochondrial pyruvate dehydrogenase complex by altering the actin cytoskeleton
The Interaction between <scp><i>HLA‐DRB1</i></scp> and Smoking in Parkinson's Disease Revisited
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression
The Parkinson’s-disease-associated mutation LRRK2-G2019S alters dopaminergic differentiation dynamics via NR2F1
Haploinsufficiency due to a novel ACO2 deletion causes mitochondrial dysfunction in fibroblasts from a patient with dominant optic nerve atrophy
Mutations in <i>RHOT1</i> Disrupt Endoplasmic Reticulum–Mitochondria Contact Sites Interfering with Calcium Homeostasis and Mitochondrial Dynamics in Parkinson's Disease
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry
NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases
Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease
Involvement of the cerebellum in Parkinson disease and dementia with Lewy bodies
An Observational Study of the Effect of Levodopa–Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson’s Disease Patients
Loss of DJ-1 impairs antioxidant response by altered glutamine and serine metabolism
The NG2 Proteoglycan Protects Oligodendrocyte Precursor Cells against Oxidative Stress via Interaction with OMI/HtrA2
Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice
Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice
Large-scale replication and heterogeneity in Parkinson disease genetic loci
A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants